Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cytochrome P450, family 3, subfamily A, polypeptide 4 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | cytochrome P450 | cytochrome P450, family 3, subfamily A, polypeptide 4 | 502 aa | 492 aa | 24.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0036 | 1 | 0.5 | |
Trypanosoma cruzi | cytochrome P450, putative | 0.0015 | 0.2051 | 0.5 |
Onchocerca volvulus | 0.0036 | 1 | 0.5 | |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0015 | 0.2051 | 0.5 |
Brugia malayi | Cytochrome P450 family protein | 0.0015 | 0.2051 | 0.2051 |
Onchocerca volvulus | 0.0036 | 1 | 0.5 | |
Trypanosoma cruzi | cytochrome P450, putative | 0.0015 | 0.2051 | 0.5 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0015 | 0.2051 | 0.2051 |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.0036 | 1 | 1 |
Onchocerca volvulus | 0.0036 | 1 | 0.5 | |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0015 | 0.2051 | 0.2051 |
Schistosoma mansoni | hypothetical protein | 0.0036 | 1 | 1 |
Brugia malayi | Cytochrome P450 family protein | 0.0015 | 0.2051 | 0.2051 |
Loa Loa (eye worm) | hypothetical protein | 0.0036 | 1 | 1 |
Onchocerca volvulus | 0.0036 | 1 | 0.5 | |
Brugia malayi | SEA domain containing protein | 0.0036 | 1 | 1 |
Leishmania major | cytochrome p450-like protein | 0.0015 | 0.2051 | 0.5 |
Trypanosoma brucei | cytochrome P450, putative | 0.0015 | 0.2051 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0015 | 0.2051 | 0.2051 |
Loa Loa (eye worm) | hypothetical protein | 0.0011 | 0.0424 | 0.0424 |
Loa Loa (eye worm) | hypothetical protein | 0.0036 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 7100 nM | BindingDB_Patents: Inhibition Assay. This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.